Literature DB >> 21998139

Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket.

Pedro Cano-Soldado1, Edurne Gorraitz, Ekaitz Errasti-Murugarren, F Javier Casado, M Pilar Lostao, Marçal Pastor-Anglada.   

Abstract

SLC28 genes, encoding concentrative nucleoside transporter proteins (CNT), show little genetic variability, although a few single nucleotide polymorphisms (SNPs) have been associated with marked functional disturbances. In particular, human CNT1S546P had been reported to result in negligible thymidine uptake. In this study we have characterized the molecular mechanisms responsible for this apparent loss of function. The hCNT1S546P variant showed an appropriate endoplasmic reticulum export and insertion into the plasma membrane, whereas loss of nucleoside translocation ability affected all tested nucleoside and nucleoside-derived drugs. Site-directed mutagenesis analysis revealed that it is the lack of the serine residue itself responsible for the loss of hCNT1 function. This serine residue is highly conserved, and mutation of the analogous serine in hCNT2 (Ser541) and hCNT3 (Ser568) resulted in total and partial loss of function, respectively. Moreover, hCNT3, the only member that shows a 2Na(+)/1 nucleoside stoichiometry, showed altered Na(+) binding properties associated with a shift in the Hill coefficient, consistent with one Na(+) binding site being affected by the mutation. Two-electrode voltage-clamp studies using the hCNT1S546P mutant revealed the occurrence of Na(+) leak, which was dependent on the concentration of extracellular Na(+) indicating that, although the variant is unable to transport nucleosides, there is an uncoupled sodium transport.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21998139     DOI: 10.1152/ajpcell.00198.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.

Authors:  C Arimany-Nardi; E Errasti-Murugarren; G Minuesa; J Martinez-Picado; V Gorboulev; H Koepsell; M Pastor-Anglada
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Molecular determinants of acidic pH-dependent transport of human equilibrative nucleoside transporter 3.

Authors:  Md Fazlur Rahman; Candice Askwith; Rajgopal Govindarajan
Journal:  J Biol Chem       Date:  2017-07-20       Impact factor: 5.157

Review 3.  Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

4.  Emerging Roles of Nucleoside Transporters.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2018-06-06       Impact factor: 5.810

Review 5.  Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29).

Authors:  Marçal Pastor-Anglada; Aida Mata-Ventosa; Sandra Pérez-Torras
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

6.  Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner.

Authors:  S Pérez-Torras; A Vidal-Pla; P Cano-Soldado; I Huber-Ruano; A Mazo; M Pastor-Anglada
Journal:  Cell Death Dis       Date:  2013-05-30       Impact factor: 8.469

7.  Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters.

Authors:  Zachary Lee Johnson; Jun-Ho Lee; Kiyoun Lee; Minhee Lee; Do-Yeon Kwon; Jiyong Hong; Seok-Yong Lee
Journal:  Elife       Date:  2014-07-31       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.